Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity

DSpace/Manakin Repository

Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity

Citable link to this page


Title: Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity
Author: Kishi, Yasuhiro; Kondo, Takaaki; Xiao, Sheng; Yosef, Nir; Gaublomme, Jellert; Wu, Chuan; Wang, Chao; Chihara, Norio; Regev, Aviv; Joller, Nicole; Kuchroo, Vijay K.

Note: Order does not necessarily reflect citation order of authors.

Citation: Kishi, Y., T. Kondo, S. Xiao, N. Yosef, J. Gaublomme, C. Wu, C. Wang, et al. 2016. “Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity.” The Journal of Experimental Medicine 213 (11): 2489-2501. doi:10.1084/jem.20151118.
Full Text & Related Files:
Abstract: Th17 cells are key players in defense against pathogens and maintaining tissue homeostasis, but also act as critical drivers of autoimmune diseases. Based on single-cell RNA-seq profiling of pathogenic versus nonpathogenic Th17 cells, we identified protein C receptor (PROCR) as a cell surface molecule expressed in covariance with the regulatory module of Th17 cells. Although PROCR expression in T cells was controlled by the cooperative action of the Th17 lineage-specific transcription factors RORγt, IRF4, and STAT3, PROCR negatively regulated Th17 differentiation. CD4+ T cells from PROCR low expressor mutant mice readily differentiated into Th17 cells, whereas addition of the PROCR ligand, activated protein C, inhibited Th17 differentiation in vitro. In addition, PROCR acted as a negative regulator of Th17 pathogenicity in that it down-regulated expression of several pathogenic signature genes, including IL-1 and IL-23 receptors. Furthermore, T cell–specific deficiency of PROCR resulted in the exacerbation of experimental autoimmune encephalomyelitis (EAE) and higher frequencies of Th17 cell in vivo, indicating that PROCR also inhibits pathogenicity of Th17 cells in vivo. PROCR thus does not globally inhibit Th17 responses but could be targeted to selectively inhibit proinflammatory Th17 cells.
Published Version: doi:10.1084/jem.20151118
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search